Harpoon Therapeutics, Inc. has filed a prospectus for the offering and resale of 25,751,025 shares of common stock by selling stockholders. This includes shares currently held, and shares issuable upon the exercise of pre-funded and common warrants. Harpoon will not sell any shares or receive proceeds from the stockholders' sales, except for net proceeds from exercised warrants. The sales may occur at various prices and through different channels. Harpoon is covering the registration costs, while selling stockholders are responsible for commissions. Harpoon's stock is listed on Nasdaq under the symbol 'HARP', with a last reported sale price of $10.00 per share as of December 6, 2023.